Wyeth says confident in Pristiq depression filing

(Reuters) - Gary Stiles, chief medical officer of Wyeth, told reporters
in a conference call the FDA has requested a new safety trial
of Pristiq for hot flashes due to elevated liver enzymes seen
in three women among 2,000 tested in Wyeth-sponsored trials of
the drug for a common symptom of menopause.




" liver enzymes are not an uncommon phenomenon"
in drug trials, Stiles said. He said elevated levels of the
enzymes -- which are considered a marker of potential damage to
the liver -- returned to normal levels when patients stopped
taking Pristiq.


Read more at Reuters.com Market News

NYSE Delays Open for Wyeth, AT&T, Jefferies on Erroneous Brokerage Orders

(Bloomberg) -- The New York Stock Exchange delayed
the open of trading in Wyeth, Jefferies Group Inc. and AT&T Inc.
after receiving erroneous orders likely generated by a computer
problem at a member firm.

The problem was identified by specialists responsible for
matching trades in the three stocks and the brokerage placing
the orders has been notified, said NYSE spokesman Richard
Adamonis. The exchange will cancel the erroneous orders, the Big
Board said in a statement.


Read more at Bloomberg Stocks News